Wong 2005.

Methods	Study design: open‐label, parallel RCT Study time frame: 2001 to 2002 Duration of follow‐up: 24 weeks
Participants	Country: Hong Kong Setting: single centre Inclusion criteria: insulin‐treated patients with type 2 DM; on CAPD therapy; stable glycaemic control (defined as HbA1c < 8% while insulin dosage is maintained at the same dose in the past 6 weeks) Number: treatment group 1 (26); treatment group 2 (26) Mean age ± SD (years): treatment group 1 (62.9 ± 7.3); treatment group 2 (61.6 ± 9.7) Sex (M/F): not reported Exclusion criteria: deranged liver function at baseline (ALT level > 2.5 times ULN); decompensated congestive heart failure
Interventions	Treatment group Rosiglitazone: 4 mg daily Insulin: intermediate acting insulin. Insulin dosage was reduced by 10% at the start of the study to minimize the risk for hypoglycaemia Control group Insulin alone: intermediate acting insulin Both groups PD prescription was kept unchanged during the study period except during episodes of fluid overload as a temporary change.
Outcomes	Change in insulin dosage at the end of the study compared with baseline dosage Change in C‐peptide, HbA1c, lipid, and high‐sensitivity CRP levels and adverse events Adverse events: defined as liver function derangement, fluid overload, and need for blood transfusion
Notes	Funding source: GLaxoSmithKline
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer generalized list was used for randomisation
Allocation concealment (selection bias)	Low risk	"Investigators were unaware of the randomisation schedule when recruiting patients"
Blinding of participants and personnel (performance bias) All outcomes	High risk	"investigators and patients were not blinded during the follow‐up period"
Blinding of outcome assessment (detection bias) All outcomes	High risk	"investigators and patients were not blinded during the follow‐up period"
Incomplete outcome data (attrition bias) All outcomes	Low risk	No discontinuations were reported
Selective reporting (reporting bias)	Unclear risk	The prespecified outcomes were available on a clinical trials database
Other bias	Low risk	Conflicts of interest: Rosiglitazone was provided by GLaxoSmithKline UK, with no other funding involved